TTKHLTCARE2024-01-012024-03-31 TTKHLTCARE2024-01-012024-03-31 TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member TTKHLTCARE2024-03-31 TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue03Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue04Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue05Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue06Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue03Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue04Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue05Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue06Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults03Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults04Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults05Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults06Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults03Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults04Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults05Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults06Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets03Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets04Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets05Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets06Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member TTKHLTCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member TTKHLTCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member TTKHLTCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities04Member TTKHLTCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities04Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities05Member TTKHLTCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities05Member TTKHLTCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities06Member TTKHLTCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities06Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 507747 TTKHLTCARE NOTLISTED TTK Healthcare Limited Equity 2023-04-01 2024-03-31 2024-05-24 2024-05-02 INR Lakhs Yearly 12:00:00 13:35:00 2024-05-24 2024-05-24 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Audited Standalone 1810563000.00 160583000.00 1971146000.00 446788000.00 402364000.00 -9301000.00 322417000.00 9296000.00 33195000.00 524124000.00 1728883000.00 242263000.00 0.00 242263000.00 59000000.00 543000.00 59543000.00 0.00 182720000.00 0.00 0.00 0.00 0.00 182720000.00 -20006000.00 162714000.00 -23269000.00 3263000.00 141303000.00 10 12.93 12.93 0.00 0.00 12.93 12.93 Notes: (1) The above financial results for the Fourth Quarter and Year ended 31st March, 2024 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 23rd May, 2024 and approved by the Board of Directors of the Company at its meeting held on 24th May, 2024 at the Registered Office of the Company, also with the provision of Video Conferencing facility. The Statutory Auditors have audited the above results and have issued an unmodified opinion. (2)(a)Profit from Discontinued Operations (pertaining to previous year (i)Gain on sale of Undertaking: During the First Quarter of FY 2022-23, the necessary formalities for transfer of the Human Pharma Division (Undertaking) of the Company were completed and the Division stood transferred as a going concern on slump sale basis, for a consideration of Rs.80,500 lakhs (final consideration of Rs.80,281.54 lakhs after working capital and other customary adjustments) to M/s.BSV Pharma Private Ltd. (BSV) with effect from 9th May, 2022 The consideration for the transfer was 74% cash (Rs.59,442.51 lakhs) and 26% in the form of equity of the buying entity. The terms of transfer also provided for purchase of the aforesaid 26% Equity Shares held by the Company in BSV, by M/s Bharat Serums and Vaccines Limited or its nominees, after they obtain necessary regulatory clearances at the issue price. During the Third Quarter of FY 2022-23, the above shares were transferred to M/s Bharat Serums and Vaccines Limited and the consideration of Rs.20,839.03 lakhs for the shares was received by the Company. The gain on sale of this Undertaking amounted to Rs.76,429.45 lakhs (after providing for Rs.1,500.00 lakhs towards contingencies of which Company had incurred expenses amounting to Rs.266.58 lakhs till 31st March, 2023). (ii)Profit from Human Pharma Division Operations: The total income of Human Pharma Division up to the date of sale (i.e.) 9th May, 2022 was Rs.2,240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1,132.29 lakhs which was no longer required) and its total expenses were Rs.1,026.10 lakhs resulting in a net profit of Rs.1,214.47 lakhs. (b)Tax expense of Discontinued Operations (pertaining to previous year): The tax expense on sale of Human Pharma Division was Rs.17,835.48 lakhs [(i.e.) Long Term Capital Gain tax expense on the above transfer amounting to Rs.17,769.26 lakhs and Deferred Tax expenses of Rs.66.22 lakhs]. The tax expense on the profit for the year ended 31st March, 2023 from the operations of Human Pharma Division was Rs.303.94 lakhs. (3)Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 lakhs in the Fourth Quarter of FY 2020-21 and proposes to take further appropriate action after the Rules are made applicable. (4)The Board has recommended a dividend of Rs.10/- (100%) per Equity Share of Rs.10/- each for the financial year ended 31st March, 2024. (5)The figures for the Quarter ended 31st March, 2024 and 31st March, 2023 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review. (6)The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. (7)This statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com). Multi segment 2023-04-01 2024-03-31 Audited Standalone 7527938000.00 626071000.00 8154009000.00 1732568000.00 1755939000.00 -105992000.00 1328400000.00 27555000.00 130587000.00 2443749000.00 7312806000.00 841203000.00 0.00 841203000.00 221000000.00 -8216000.00 212784000.00 0.00 628419000.00 0.00 0.00 0.00 0.00 628419000.00 -11768000.00 616651000.00 -14390000.00 2622000.00 141303000.00 10 9823743000.00 44.47 44.47 0.00 0.00 44.47 44.47 Other Expenses 524124000.00 Other Expenses 2443749000.00 748000000.00 7902000.00 0.00 0.00 58000.00 0.00 0.00 0.00 125580000.00 0.00 0.00 258135000.00 383715000.00 54435000.00 38848000.00 1232958000.00 969898000.00 0.00 864402000.00 109593000.00 7639810000.00 0.00 997777000.00 9611582000.00 8550000.00 182959000.00 10772989000.00 0.00 0.00 12005947000.00 141303000.00 9867886000.00 10009189000.00 10009189000.00 0.00 0.00 7987000.00 7987000.00 30607000.00 0.00 0.00 0.00 38594000.00 214730000.00 1022620000.00 493088000.00 1730438000.00 41137000.00 186589000.00 0.00 0.00 1958164000.00 0.00 0.00 1996758000.00 12005947000.00 Animal Welfare 289939000.00 Consumer Products 505259000.00 Foods 332189000.00 Medical Devices 198823000.00 Others 1101000.00 Protective Devices 483252000.00 Animal Welfare 1155145000.00 Consumer Products 2323733000.00 Foods 1241433000.00 Medical Devices 804904000.00 Others 4077000.00 Protective Devices 1998646000.00 1810563000.00 7527938000.00 0.00 0.00 1810563000.00 7527938000.00 Animal Welfare 43156000.00 Consumer Products 38197000.00 Foods -8102000.00 Medical Devices 40566000.00 Others 948000.00 Protective Devices 56002000.00 Animal Welfare 105095000.00 Consumer Products 162159000.00 Foods -31068000.00 Medical Devices 169289000.00 Others -6474000.00 Protective Devices 159552000.00 170767000.00 558553000.00 9296000.00 27555000.00 -80792000.00 Notes: 1.Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management. 2.Details of products included in each of the Segments are as below : i)Animal Welfare (earlier included in Pharmaceuticals Segment) comprise products for Veterinary use. ii)Consumer Products comprise marketing and distribution of Woodward's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc. iii)Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc. iv)Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products. v)Foods comprise manufacturing and marketing of Food Products. vi) Others include Printing and Publishing of Maps and Atlases. vii)Human Pharma (earlier included in Pharmaceuticals Segment) comprise products for Human use 3.(a) Segment Results of Human Pharma Division include gain on sale of the division amounting to Rs.76,429.45 lakhs in the previous year. (b) Unallocated Segment Assets include consideration on sale of Human Pharma Division and unallocated revenue / cost includes return thereon. 4.The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment. 5.The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. -310205000.00 242263000.00 841203000.00 Animal Welfare 399999000.00 Consumer Products 470291000.00 Foods 672770000.00 Medical Devices 640949000.00 Others 28156000.00 Protective Devices 1229307000.00 3441472000.00 8564475000.00 12005947000.00 Animal Welfare 311658000.00 Consumer Products 697015000.00 Foods 162388000.00 Medical Devices 104852000.00 Others 15088000.00 Protective Devices 363164000.00 1654165000.00 342593000.00 1996758000.00 27555000.00 -124752000.00 51449000.00 0.00 -1776000.00 1802000.00 -1097000.00 -985000.00 0.00 -85491000.00 0.00 4726000.00 0.00 130587000.00 260000.00 2868000.00 324000.00 -412000.00 0.00 -462000.00 1081000.00 621090000.00 0.00 0.00 0.00 0.00 0.00 -23492000.00 0.00 -641067000.00 200136000.00 0.00 0.00 0.00 249569000.00 0.00 -49433000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1255000.00 103834000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1081000.00 573357000.00 0.00 -186924000.00 0.00 284935000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 40553000.00 5844000.00 0.00 141303000.00 31412000.00 0.00 0.00 -219112000.00 16390000.00 0.00 16390000.00 93203000.00 109593000.00 -23269000.00 -14390000.00 -3263000.00 -2622000.00 0.00 0.00